Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HEMUP is an oral hematinic supplement developed by Parnasa Mediworld, specifically formulated to address iron deficiency and support overall nutritional status. The product is a combination of ferrous ascorbate, folic acid (Vitamin B9), and zinc. Ferrous ascorbate provides a highly bioavailable form of elemental iron, which is a critical component of hemoglobin required for oxygen transport in the blood. Folic acid is essential for DNA synthesis and the maturation of red blood cells, helping to prevent megaloblastic anemia. Zinc is included as a vital trace mineral that acts as a cofactor for numerous enzymes involved in cellular metabolism, protein synthesis, and immune function. HEMUP is primarily indicated for the treatment and prevention of iron-deficiency anemia, particularly during pregnancy, lactation, or recovery from surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ferrous ascorbate + folic acid + zinc.